Literature DB >> 17235637

Suspected paclitaxel-induced pneumonitis.

Kohei Shitara1, Eiji Ishii, Makoto Kondo, Yuh Sakata.   

Abstract

We report two patients with advanced gastric cancer with suspected paclitaxel-induced interstitial pneumonitis. Case 1, a 66-year-old man with recurrent gastric cancer, was treated weekly with paclitaxel. After 11 administrations of paclitaxel, he developed a nonproductive cough and dyspnea. Computed tomography (CT) scan showed extensive bilateral areas of ground-glass attenuation. He did not respond to corticosteroid, and died 57 days after the last paclitaxel administration. Case 2, a 61-year-old man with gastric cancer and liver metastasis, was treated with weekly paclitaxel. The liver metastasis was dramatically reduced in size, but he developed a nonproductive cough and dyspnea after 21 administrations of paclitaxel. He did not respond to high-dose corticosteroid, and died 50 days after the last paclitaxel administration. Although it is a rare complication, paclitaxel-induced interstitial pneumonitis needs to be considered in the differential diagnosis when patients treated with paclitaxel present with fever, nonproductive cough, and dyspnea.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17235637     DOI: 10.1007/s10120-006-0388-1

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  9 in total

1.  Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study.

Authors:  A L Thomas; G Cox; R A Sharma; W P Steward; F Shields; K Jeyapalan; S Muller; K J O'Byrne
Journal:  Eur J Cancer       Date:  2000-12       Impact factor: 9.162

2.  [A case of drug-induced interstitial pneumonitis after gemcitabine treatment for advanced pancreatic cancer].

Authors:  Masaya Nomura; Yoshifumi Inoue; Shigeo Fujita; Jun Sakao; Masaki Hirota; Shigeo Souda
Journal:  Gan To Kagaku Ryoho       Date:  2006-01

3.  Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis.

Authors:  K B Baumgartner; J M Samet; C A Stidley; T V Colby; J A Waldron
Journal:  Am J Respir Crit Care Med       Date:  1997-01       Impact factor: 21.405

4.  Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel.

Authors:  A G Taghian; S I Assaad; A Niemierko; I Kuter; J Younger; R Schoenthaler; M Roche; S N Powell
Journal:  J Natl Cancer Inst       Date:  2001-12-05       Impact factor: 13.506

5.  Severe interstitial pneumonitis associated with docetaxel administration.

Authors:  William L Read; Joanne E Mortimer; Joel Picus
Journal:  Cancer       Date:  2002-02-01       Impact factor: 6.860

Review 6.  An overview of experience with TAXOL (paclitaxel) in the U.S.A.

Authors:  R C Donehower; E K Rowinsky
Journal:  Cancer Treat Rev       Date:  1993       Impact factor: 12.111

7.  Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages.

Authors:  C Bogdan; A Ding
Journal:  J Leukoc Biol       Date:  1992-07       Impact factor: 4.962

8.  Hypersensitivity reactions from taxol.

Authors:  R B Weiss; R C Donehower; P H Wiernik; T Ohnuma; R J Gralla; D L Trump; J R Baker; D A Van Echo; D D Von Hoff; B Leyland-Jones
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

9.  Paclitaxel-induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy.

Authors:  K Fujimori; A Yokoyama; Y Kurita; K Uno; N Saijo
Journal:  Oncology       Date:  1998 Jul-Aug       Impact factor: 2.935

  9 in total
  2 in total

1.  Predictive factors for radiation pneumonitis in oesophageal cancer patients treated with chemoradiotherapy without prophylactic nodal irradiation.

Authors:  M Nomura; T Kodaira; K Furutani; H Tachibana; Natsuo Tomita; Y Goto
Journal:  Br J Radiol       Date:  2012-01-17       Impact factor: 3.039

2.  Induction and concurrent taxanes enhance both the pulmonary metabolic radiation response and the radiation pneumonitis response in patients with esophagus cancer.

Authors:  Matthew McCurdy; Mary Frances McAleer; Wei Wei; Muthuveni Ezhil; Valen Johnson; Meena Khan; Jamie Baker; Dershan Luo; Jaffer Ajani; Thomas Guerrero
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-06-12       Impact factor: 7.038

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.